Why medical cannabis packaging poses accessibility challenges and how we can fix it

2w
4m read
Summary

In practice, “patients are being penalized for using cannabis over traditional pharmaceuticals,” says Trina Fraser, Cannabis Regulatory Expert, Partner at Brazeau Seller law and Board Member of Medical Cannabis Canada. The Cannabis Act was developed with the purpose of preventing youth access, protecting public health, curbing the illicit market and ensuring the medical stream is not misused. The Cannabis Act is structured so that the medical side mirrors the non-medical system, with the stated intention to reduce the incentive for people to access the medical stream for non-medical purposes.   Max Monahan-Ellison is a healthcare strategist specializing in highly stigmatized areas, Co-founder and partner at medical cannabis and emerging therapeutics consulting firm, eCB Consulting Inc., and Board Member of national non-profit, Medical Cannabis Canada. ( function() { pnLoadVideo( "videos", "G9AJCgbMivg", "pn_video_270699", "", "", {"controls":1,"autoplay":0,"is_mobile":""} ); } )(); Subscribe to  Weekend Dispensary, a new weekly newsletter from The GrowthOp. A 2019 survey from Health Canada estimates that around a third of patients use cannabis to manage arthritis symptoms and similar proportions for chronic and acute pain.

Article Preview

This story is a part of the TGO column Medical Cannabis in Canada that takes a deep dive into the sector from the perspectives of patients, healthcare professionals, policymakers, researchers and professionals that navigate it.

'This approach to labelling is misleading Canadian cannabis consumers' Give Canadian...

Read the full article @ The Growth Op